Patents Assigned to Ignite Immunotherapy, Inc.
  • Recombinant vaccinia virus and methods of use thereof
    Patent number: 11685904
    Abstract: The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus, compositions comprising the vaccinia virus, and use of the vaccinia virus or composition for inducing oncolysis in an individual having a tumor.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: June 27, 2023
    Assignee: Ignite Immunotherapy, Inc.
    Inventors: David H. Kirn, Liliana Maruri Avidal, Prajit Limsirichai
  • Recombinant vaccinia virus and methods of use thereof
    Patent number: 11529402
    Abstract: The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus; and compositions comprising the replication-competent, recombinant oncolytic vaccinia virus. The present disclosure also provides use of the vaccinia virus or composition for inducing oncolysis in an individual having a tumor.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: December 20, 2022
    Assignee: Ignite Immunotherapy, Inc.
    Inventors: Douglas Hanahan, David H. Kirn, Liliana Maruri Avidal, Michael D. Eisenbraun, Joseph J. Binder, Clare Lees
  • RECOMBINANT VACCINIA VIRUS AND METHODS OF USE THEREOF
    Publication number: 20200263145
    Abstract: The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus, compositions comprising the vaccinia virus, and use of the vaccinia virus or composition for inducing oncolysis in an individual having a tumor.
    Type: Application
    Filed: February 10, 2020
    Publication date: August 20, 2020
    Applicant: Ignite Immunotherapy, Inc.
    Inventors: David H. Kirn, Liliana Maruri Avidal, Prajit Limsirichai
  • RECOMBINANT VACCINIA VIRUS AND METHODS OF USE THEREOF
    Publication number: 20200222520
    Abstract: The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus; and compositions comprising the replication-competent, recombinant oncolytic vaccinia virus. The present disclosure also provides use of the vaccinia virus or composition for inducing oncolysis in an individual having a tumor.
    Type: Application
    Filed: January 9, 2020
    Publication date: July 16, 2020
    Applicant: Ignite Immunotherapy, Inc.
    Inventors: Douglas Hanahan, David H. Kirn, Liliana Maruri Avidal, Michael D. Eisenbraun, Joseph J. Binder, Clare Lees